Omega Healthcare Investors enters the back half of June with a quietly building short position, a significant CEO sale on record, and a split analyst community — all while the stock drifts 4% below its one-month high.
The most notable development in positioning is how quickly shorts have rebuilt. Short interest has climbed 15% over the past month to reach 4.7% of the free float — roughly 13.8 million shares. The bulk of that move came in a single step: short interest jumped from around 12.9 million shares to nearly 13.7 million in the week of June 9-16 alone, a 7% weekly increase. That pace of accumulation is worth watching for a stock that had been relatively stable through most of May. The borrow market itself is not under any stress — availability is extremely loose at over 1,300% of short interest, meaning there are roughly 13 shares available for every one already shorted, and borrowing costs remain negligible at 0.44%. The supply for new short positions is ample. Options, meanwhile, are leaning mildly bullish: the put/call ratio has slipped to 0.48, slightly below its 20-day average and near the lower end of its recent range, suggesting no particular hedging urgency among options traders.
The Street is sending mixed signals. Raymond James reinstated coverage on June 17 with an Outperform and a $50 target — a constructive read that slots comfortably above the current $45.50 price. But Truist trimmed its target from $48 to $46 just last week while keeping a Hold. The mean price target across the analyst community sits around $50.90, implying about 12% upside from current levels, though the distribution of views is wide: UBS carries a Buy with a $54 target, while Bank of America holds an Underperform at $46 — essentially flat to today's price. The bull case rests on Omega's portfolio scale (929 facilities, 94 operator partners), active acquisition pace across the US, UK, and Canada, and a dividend score that ranks in the 89th percentile of the universe. The bear case is less about the model and more about tail risk: tenant stability concerns, the ongoing Genesis bankruptcy process, and a reimbursement environment that continues to pressure operator margins. EPS momentum factor scores are weak — both 30-day and 90-day readings rank in the 17th percentile — pointing to a string of downward estimate revisions in recent months.
The insider picture tilts negative in the near term. CEO C. Taylor Pickett sold 112,500 shares on June 1 at $47.94, a transaction worth $5.4 million — and that follows a $8.85 million sale in late December at $44.25. The 90-day net insider position is a net sale of over 112,000 shares. The contrast with late 2025 is worth noting: Pickett had actually bought 20,000 shares in early November at around $43.14, as did CIO Vikas Gupta with an 11,500-share purchase at similar levels. That buying cluster in November — when the stock was in the low $40s — has since been followed by two material CEO sales at higher prices, suggesting the November buyers viewed $43 as an opportunity that has now largely been realised.
Among peers, the week has been notably softer for SBRA and CTRE, both down roughly 1.8%, while WELL gained 3.3% and VTR added 1.7%. OHI's flat-to-down week sits in the weaker half of the healthcare REIT cohort, consistent with a stock where the rebuilding short position and the CEO's recent sell are weighing on sentiment even as the dividend yield and Raymond James reinstatement provide a floor.
The next earnings event is scheduled for July 31 — at that point, the Street will want answers on operator rent collection trends, any update on the Genesis situation, and whether the investment pipeline justifies the mid-teens IRR targets management has cited; the pace of short rebuilding between now and then will be a live indicator of how much conviction the bears are accumulating ahead of that print.
See the live data behind this article on ORTEX.
Open OHI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
